# Vitamin D Cognitive Performance Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/vitamin-d-cognitive-performance-meta-analysis-evidence-review
Category: evidence-review
Summary: Vitamin D Cognitive Performance Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pa
Last reviewed: 2026-08-16
Reviewed by: Migaku Evidence Review
# Vitamin D Cognitive Performance Meta-analysis: What the Evidence Says

## Quick Answer

Vitamin D Cognitive Performance Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 2 systematic review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Maternal vitamin B12, vitamin D, and folic acid status during pregnancy and child neurodevelopment: a systematic review | systematic review | 1 | 2026-06-10 | 10.3389/fnins.2026.1825297 |
| Effects of dietary supplements on cognitive outcomes and physiological biomarkers in mild cognitive impairment: a systematic review and network meta-analysis | systematic review | 1 | 2026-04-29 | 10.3389/fnut.2026.1775177 |

## What The Sources Report

- Insufficient maternal B12 levels have been associated with impaired neuronal maturation, altered neurotransmitter synthesis, and disruptions in cognitive and language development. [Franco Lívia (2026); evidence level 1]
- Evidence from cohort studies indicates that children born to mothers with suboptimal B12 status exhibit lower cognitive performance, reduced attention, and poorer academic outcomes (;;;). [Franco Lívia (2026); evidence level 1]
- ω Current pharmacological treatments for MCI, such as cholinesterase inhibitors and memantine, have shown limited effectiveness in delaying disease progression and are frequently associated with adverse effects, which contribute to poor patient adherence. [Wang Xiaolong (2026); evidence level 1]
- ω During the onset and progression of MCI, several physiological biomarkers, including reduced BDNF levels (reflecting impaired neurogenesis), elevated amyloid-β peptides (Aβ42 and Aβ40), and abnormal oxidative stress markers, serve as objective indicators for evaluating intervention efficacy. [Wang Xiaolong (2026); evidence level 1]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For vitamin d cognitive performance meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Franco Lívia (2026). Maternal vitamin B12, vitamin D, and folic acid status during pregnancy and child neurodevelopment: a systematic review. DOI: 10.3389/fnins.2026.1825297. PMCID: PMC13290869. PMID: 42359342. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13290869/
- Wang Xiaolong (2026). Effects of dietary supplements on cognitive outcomes and physiological biomarkers in mild cognitive impairment: a systematic review and network meta-analysis. DOI: 10.3389/fnut.2026.1775177. PMCID: PMC13167511. PMID: 42137868. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13167511/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.